Henry Schein management check

HSIC · Health Care · Health Care Distributors · CEO Mr. Bergman

Filings as of

50
Management score, ranked 419th of 487Strongest: dilution. Weakest: CEO cost. See the best and worst run in Health Care →

2 good · 3 to watch · 2 flagged, across the seven questions below.

  • Watch

    Have owners done well?

    Trailed its chosen peers

    $100 invested at the start of fiscal 2021 grew to $116, against $144 for the peer group the company picked itself.

  • Watch

    Does pay follow performance?

    Pay only loosely tracked returns

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.01 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    2.9% of net income

    $12.0m of reported pay in fiscal 2025, against $419.0m of net income.

  • Good

    Do they own the stock?

    Insiders are buying

    1 insider bought $692k on the open market in the last six months, with their own money, near the lows.

  • Good

    Are owners being diluted?

    Share count shrinking

    Diluted shares changed -3.9% a year over the last three fiscal years. Stock-based pay was 0.3% of revenue in the latest year.

  • Flag

    Is leadership stable?

    14 leadership filings in 3 years

    CEO in the pay table: Mr. Bergman. 14 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Flag

    Are the books clean?

    Red flags on file

    1 late-filing notice since 2021.

Against the S&P 500

Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.

CheckScoreAt or aboveSector median
Owner returns2633%26
Pay for performance5113%85
CEO cost1220%44
Skin in the game8094%46
Dilution9988%68
Stable leadership5530%70
Clean books307%100

Closest peers

Others in Health Care Distributors, by management score. Henry Schein is 51st of 60 in its sector.

  1. 45CAHCardinal Health81
  2. 150MCKMcKesson72
  3. 233CORCencora66
  4. 419HSICHenry Schein50
  5. 422TECHBio-Techne50
  6. 431ZBHZimmer Biomet49

Pay versus performance

From the proxy statement filed April 8, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.

CEO pay by fiscal yearAs reported Actually paid
$0$14.1m$28.3m20212022202320242025
What $100 becameCompany Peer group
$10020212022202320242025$116
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Bergman$12.0m$9.8m$3.3m$116$144$419.0m
2024—$11.6m$7.9m$3.2m$107$126$398.0m
2023—$10.0m$4.9m$2.8m$115$122$436.0m
2022—$8.3m$10.0m$2.9m$121$120$566.0m
2021—$10.8m$28.3m$3.9m$114$124$660.0m

The board says pay is tied most to Non-GAAP EPS. Its other key measures: Adjusted EPS, Revenues, Adjusted Operating Income, Return on Invested Capital.

Insiders and the CEO's stake

1 insider bought $692k on the open market in the last six months, with their own money, near the lows.

  • BoughtWilliam K DanielDirector$692kMay 11, 2026

Leadership and governance on file

Latest shareholder vote results: May 22, 2026, including the say-on-pay vote.

Where the money went

Over 2021–2025: $2.4bn returned to owners in buybacks and dividends, 96% of net income, and $249.0m of pay in stock.

Fiscal year20212022202320242025
Revenue$12.4bn$12.6bn$12.3bn$12.7bn$13.2bn
Net income$660.0m$566.0m$436.0m$398.0m$419.0m
Stock-based pay$78.0m$54.0m$39.0m$39.0m$39.0m
Buybacks$401.0m$485.0m$250.0m$385.0m$850.0m
Dividends—————
Diluted shares142m138m132m128m122m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.